AxoGen Inc AXGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/25/24 EDT
6.52UNCH (UNCH)
Volume
65,285
Close
6.52UNCH (UNCH)
Volume
167,648
52 week range
3.45 - 10.83
Loading...
  • Open6.72
  • Day High6.87
  • Day Low6.46
  • Prev Close6.87
  • 52 Week High10.83
  • 52 Week High Date02/27/24
  • 52 Week Low3.45
  • 52 Week Low Date11/01/23

Key Stats

  • Market Cap281.705M
  • Shares Out43.21M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-4.54

KEY STATS

  • Open6.72
  • Day High6.87
  • Day Low6.46
  • Prev Close6.87
  • 52 Week High10.83
  • 52 Week High Date02/27/24
  • 52 Week Low3.45
  • 52 Week Low Date11/01/23
  • Market Cap281.705M
  • Shares Out43.21M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-4.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.51
  • P/E (TTM)-12.86
  • Fwd P/E (NTM)-49.39
  • EBITDA (TTM)-16.97M
  • ROE (TTM)-22.08%
  • Revenue (TTM)159.012M
  • Gross Margin (TTM)78.46%
  • Net Margin (TTM)-13.66%
  • Debt To Equity (MRQ)48.74%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AxoGen Inc

 

Profile

MORE
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed...
Karen Zaderej
Chairman of the Board, President, Chief Executive Officer
Nir Naor CPA
Chief Financial Officer
Marc Began
Executive Vice President, Chief Compliance Officer, General Counsel
Address
SUITE 100, 13859 PROGRESS BLVD.
Alachua, FL
32615
United States